In recent years, immunosuppressive medication modification including CNI-free regimens, substitution by mammalian target of rapamycin inhibitors or reduction in dosage of immunosuppression has been utilized as a treatment after cancer diagnosis in some transplant patients.[34,35] It has been speculated that the use of rapamycin, instead of CNI might reduce the recurrence of cancer in transplant patients.[36] In a case of adenocarcinoma in the stage of III B, as in our patient, switching immunosuppression regimen from cyclosporin to rapamycin might be helpful for his survival after surgery. This evidence concerns the gene MTOR and cancer.